Express Pharma - Express Pharma

GBR 1342 is one of three investigational immuno-oncology agents based on Glenmark’s proprietary BEAT platform

Under the terms of agreement, SUDA will receive an upfront cash payment of $ 0.4 million and a further payment of $ 0.6 million on…

With these promising observations, Dr Gopinath and his team are planning next stage animal studies for further evaluation of these…

High blood pressure, smoking and diabetes increase heart attack risk more in women than in men

The company did not provide any details on the magnitude of risk reduction seen in the so-called outcomes trial

BioProduction’s content platform will be added to the bioLIVE exhibition, creating one of the world’s largest event hubs for the…

Dupixent was launched in the US in April 2017 for the treatment of moderate-to-severe eczema The US Food & Drug…

Unichem and Optimus company has entered into an agreement to acquire 20 per cent equity stake in the API

These patents are valid through 2036 and 2034 respectively